Nurix’s NX-2127 is an orally bioavailable BTK degrader that exhibits in vivo degradation across species and has advanced into first-in-human clinical trials for relapsed/refractory B-cell malignancies. This molecule one-pager serves as a reference guide, offering an overview of the scientific significance of Nurix's NX-2127 program. It includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.
This table contains a list of some of the best drug discovery websites, online databases, and other online resources for drug hunters everywhere. If you have a suggestion for websites that we may have missed, let us know!
It's hard not to think about infectious diseases at the moment, but it's a great time to review the drug discovery literature. One area of drug discovery that has deep roots in infectious disease research is targeted covalent inhibition. Targeted covalent inhibitors form covalent bonds with discrete targets (as opposed to [...]
This article explains what LogD is, why LogD (or LogP) is important in drug discovery, rookie mistakes in drug discovery that come from overlooking LogD or LogP, and contains a LogD reference poster that shows the estimated amount of potency attributable to lipophilicity considerations alone. By Dennis Hu Jump to Cheat Sheet Lipophilicity is [...]
This table features a selection of some of the best books on drug discovery, as well as related topics such as pharmacology, toxicology, pharmaceutics, and biotech. While nothing can replace hands-on industry experience, a few books serve as valuable references and offer insights into the realities of drug discovery. We recommend this list as a useful technical resource or as an informative introduction to the broader field of drug discovery, beyond any single discipline.
